GlassScriptPhysician profile
Cesar Garcia
NPI 1912534819
$8,906.90
in general payments reported to CMS, 2019-2025
21 companies · $801 in 2025
The $801 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.14 · 2022: $1,569 · 2023: $5,291 · 2024: $1,224 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,992 · Travel and Lodging: $3,162 · Education: $161.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,991.74 |
| Travel and Lodging | $3,162.38 |
| Education | $161.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $4,748.18 | 2022-2023 | Propel, Nuvent, Sinuva |
| Optinose US, INC. | $1,470.45 | 2022-2025 | |
| Novo Nordisk INC | $526.22 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $331.41 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $318.43 | 2024-2025 | Otezla, Evenity, Repatha |
| Inspire Medical Systems, INC. | $299.98 | 2023-2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $169.08 | 2022-2023 | Dupixent |
| Abbvie INC. | $158.95 | 2024 | |
| Lilly USA, LLC | $144.48 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Stryker Corporation | $131.69 | 2022 | |
| Glaxosmithkline, LLC. | $127.58 | 2021-2025 | Arexvy, Shingrix, Nucala |
| Otsuka America Pharmaceutical, INC. | $105.16 | 2024-2025 | Rexulti |
| Phadia US INC. | $91.25 | 2022-2023 | Immunocap |
| Dexcom, INC. | $48.42 | 2025 | Dexcom G6 Transmitter |
| Acclarent, INC | $44.72 | 2023 | Trudi Nav Cable |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $39.12 | 2025 | Freestyle Libre, Freestyle Libre 3 |
| Olympus America INC. | $37.71 | 2023 | Rhino-Laryngo Videoscope |
| Orthofix Medical, INC. | $35.49 | 2023 | Spinal-Stim, Cervical-Stim |
| Astellas Pharma US INC | $33.68 | 2024 | Veozah |
| Boston Scientific Corporation | $26.84 | 2025 | Therasphere Y90 Glass Microspheres 7.0 Gbq (US Commercial) |
| Sumitomo Pharma America, INC. | $18.06 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cesar Garcia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.